# MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Source: https://onco.cc/trials/nct07479485/  
OnCo record `nct07479485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pucotenlimab, Bevacizumab in hepatocellular carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) is a phase 1/2 interventional study registered as NCT07479485 by Lepu Biopharma Co., Ltd., with 160 participants planned, started 2026-04-08 and due to reach its primary completion in 2028-04. Interventions recorded: MRG006A, Pucotenlimab, Bevacizumab, PD1/VEGF antibody, TKI. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07479485
- Phase: 1/2
- Setting: An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07479485: https://clinicaltrials.gov/study/NCT07479485

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07479485.json